QUOTE AND NEWS
FiercePharma  11 hrs ago  Comment 
The top 10 companies producing diabetes meds raked in about $62 billion in global sales in 2014, up 5.1% from the previous year, according to a report from data analytics firm GlobalData. Companies such as Novo Nordisk, Sanofi and Merck lead the...
Market Intelligence Center  Jun 24  Comment 
The patented option trade-picking algorithms behind MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered call trade on Sanofi-Aventis (SNY) that includes 4.69% downside protection. Sell one contract of the Aug. '15...
Market Intelligence Center  Jun 23  Comment 
Sanofi-Aventis (SNY) presents a trading opportunity that offers a 3.39% return in just 87 days. A covered call on Sanofi at the $50.00 level expiring on Sep. '15 offers an assigned return rate of 3.39% or 14.23% annualized. This trade offers...
FierceBiotech  Jun 23  Comment 
As CEO of Sanofi, Chris Viehbacher was always an outspoken champion of the innovation that could be found in biotech, even as it remained an elusive goal inside the Big Pharma. He backed up that belief with major partnerships with the likes of...
FiercePharma  Jun 22  Comment 
Early on in the cancer drug pricing debates, doctors at Memorial Sloan Kettering Cancer Center made waves by rejecting a new Sanofi colon cancer drug as too expensive for its benefits. Now, the noted hospital has taken its cost-benefit analysis to...
FierceBiotech  Jun 18  Comment 
In this week's EuroBiotech Report, Neil Woodford's fund got deeper into Circassia, pulled out of Sanofi and criticized GlaxoSmithKline for performing "poorly operationally." Servier scooped up regional rights to Taiho Pharmaceutical's refractory...
FiercePharma  Jun 18  Comment 
It's no secret that Big Pharma isn't winning the popularity contest, as pricing pressures, safety issues and regulatory drama continue to take their toll on drugmakers' reputations. But some companies are faring better than other in the eyes of...
GenEng News  Jun 18  Comment 
Scientists at the University of California, San Diego School of Medicine (UCSD) reported the results of a proof-of-principle study with a small group of metastatic colorectal cancer patients to better predict how patients will respond to...




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki